WASHINGTON, Sept. 26 -- National Institutes of Health has issued a notice called: Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Development of Zika Virus Strains for Use in Oncolytic Therapy.
The notice was published in the Federal Register on Sept. 26 by Surekha Vathyam, Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.
Summary: The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Advocate Aurora Research Institute, located in Milwa...